Filana Therapeutics, Inc.
FLNA
$0.97
-$0.03-2.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -27.31% | 17.93% | |||
| Gross Profit | 27.31% | -17.93% | |||
| SG&A Expenses | -8.06% | 16.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.89% | 16.92% | |||
| Operating Income | 15.89% | -16.92% | |||
| Income Before Tax | 16.73% | 17.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 16.73% | 17.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.73% | 17.61% | |||
| EBIT | 15.89% | -16.92% | |||
| EBITDA | 16.26% | -18.94% | |||
| EPS Basic | 16.74% | 17.60% | |||
| Normalized Basic EPS | 16.75% | -21.00% | |||
| EPS Diluted | 15.85% | 17.76% | |||
| Normalized Diluted EPS | 16.75% | -21.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||